The system is said to offer scientists an important and unique tool for drug discovery. The VenaFlux is simple to use, reduces costly layers of animal model studies, and delivers specific, accurate, and reproducible results. Using the VenaFlux, scientists can rapidly obtain quantitative analyses and results for potential drug candidates in therapeutic areas including cardiovascular, respiratory, immunologic, autoimmune and oncologic disease states.
Vivienne Williams, CEO of Cellix, said: “Our VenaFlux accurately replicates cell behavior in human capillaries, an in vitro modeling system that has previously been difficult to achieve.”